Company Overview
Cryo-Cell International, Inc. engages in the provision of cord blood and cord tissue cryopreservation services within the United States, offering cellular processing and cryogenic storage solutions primarily for family use. The company focuses on the collection and preservation of umbilical cord blood and tissue stem cells, serving a niche within the broader healthcare landscape. Operating within the Healthcare sector and specifically the Medical Care Facilities industry, the company leverages specialized biological storage technology to meet specific preservation needs. The company currently maintains a market capitalization of $26.66M and reports an annual revenue of $31.57M while employing 72 individuals. These valuation and revenue figures indicate that Cryo-Cell is a mid-sized entity with a relatively modest operational scale compared to large-cap healthcare conglomerates. The market cap suggests a smaller market presence where the company's growth trajectory and profitability are critical drivers of its valuation rather than established dominance in a saturated market.
Financial Health
The company reported revenue of $31.57M over the trailing twelve months, yet recorded a net income of $-2,429,385, revealing a significant gap between top-line generation and bottom-line profitability. This disparity highlights a cost structure where operating expenses substantially exceed gross profits, resulting in an operating loss that erodes the bottom line. Despite the net loss, the company generated an EBITDA of $1.47M, which provides a view of operational cash generation before interest and taxes. The free cash flow stands at $580,321, indicating that the business generates positive cash from operations sufficient to cover capital expenditures and maintain financial flexibility. Analyzing the margin profile, the gross margin is 62.8%, suggesting that the core service of cryopreservation retains high value before overhead costs. However, the operating margin is -50.6% and the profit margin is -7.7%, indicating that high fixed costs or administrative expenses are negatively impacting overall profitability. Regarding liquidity and leverage, the company holds $3.30M in cash against $11.56M in debt, while the debt-to-equity ratio is listed as N/A due to the negative equity position. The current ratio is 0.59, which indicates that the company's current assets are insufficient to cover its current liabilities without external financing or asset liquidation. Return on Equity is N/A because of the negative shareholders' equity, while the return on assets is 0.5%, revealing that management is generating minimal returns on the asset base relative to the capital deployed.
Valuation Assessment
The trailing P/E ratio is N/A given the negative net income, whereas the forward P/E is 41.38, implying that the market prices in future earnings expectations that are significantly higher than current performance. The price-to-book ratio is -1.43, which indicates that the market valuation is negative relative to the company's book value, a metric often seen in distressed or unprofitable biotechnology firms. Alternative valuation metrics such as the price-to-sales ratio of 0.84 and an EV/EBITDA of 23.80 provide context for the company's pricing relative to its sales volume and earnings power. The 52-week high is $6.79 and the 52-week low is $2.87, meaning the stock trades within a range where the current price sits at a specific point relative to these extremes. The beta is 0.68, suggesting that the stock exhibits lower price volatility relative to the broader market, moving less than the general index during periods of market fluctuation. These valuation metrics collectively suggest that the market is compensating for current losses with expectations of future operational improvements, despite the high forward multiple.
Growth & Income
Revenue growth year-over-year is -2.3%, while earnings growth is N/A due to the negative earnings baseline, indicating that the company is currently contracting in terms of sales volume. The absence of earnings growth data alongside negative revenue growth implies that the business is facing headwinds that are affecting both top-line expansion and bottom-line viability. Regarding income distribution, the company offers a dividend yield of 18.1% with a payout ratio of 3962.9%, which is unsustainable given the negative net income of $-2,429,385. This high payout ratio in the context of losses suggests the dividend is not backed by current earnings and poses a risk of future reduction. Consequently, the company's overall growth and income profile reflects a challenging environment characterized by revenue contraction and an aggressive, potentially unsustainable dividend policy that does not align with traditional profitability metrics.